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ABSTRACT
Background
Until several years ago, interferon alfa was the only drug with proven benefit for the treatment of chronic
Hepatitis C. Several therapy categories such as fixed-dose regimens, induction-dose regimens and
escalation-dose regimens are already known. With standard dose interferon therapy of 3 MU, TIW for 6
months, a sustained response rate can ve achieved in only 10-20% of patients. This study reports the results
of treatment of chronic Hepatitis C with high dose interferon therapy of 6 MU, TIW for 6 months.
Patients and Methods
From February 1996 to February 1998, 15 patients with Hepatitis C were treated with interferon alfa-2b
6 MU, TIW for 6 months. Ultrasound-guided liver-biopsy was performed using the Menghini-Technique
(Hepafix). Virological and biochemical responses were assessed at the end of the treatment period at week
24 and at the end of follow-up period at  week 48 and up to 2 years later. Virological and biochemical
sustained responses were defined as the absence of HCV-RNA, and SGPT concentration within the normal
range at both weeks 24 and 48. Histological response was assessed after the end of treatment. Side-effects
were observed and noted.
Results
Ten out of 15 patients (66.7%) were HCV-RNA negative and 11 out of 15 patients (73.3%) demonstrated
ALT within the normal range at week 24. At the end of the follow-up, from week 48 until 2 years later, HCV-
RNA negative and normal ALT were found in 6 patients (40%). Histological improvement was found in 4 out
of 6 patients. Fever was the most common side-effect and was found in 13 patients, while fatigue was found
in 12 patients, myalgia in 11, headache in 10, and anorexia in 11 patients.
Conclusion
High dose interferon alfa-2b therapy for the treatment of chronic Hepatitis C can improve the rate of
sustained response, but is associated with more side-effects.
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INTRODUCTION
Until several years ago Interferon alfa was the only
drug with proven benefit for the treatment of chronic
Hepatitis C.
After the first administration of Interferon for the
treatment of Hepatitis NANB by Hoofnagle et al, in
19861, multicenter studies have been done to find out the
optimal dose.
Since several years some therapy regimes with
difference dose including high dose are already known
such as: (1) fixed-dose regime with 3, 5 or 10 MU, TIW
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or 3-5 MU, QD for 6 months; (2) induction-dose regime
with 5-10 MU, QD or TIW for 2-8 weeks continued
with the same or lower dose TIW for 8-22 weeks; (3)
escalation-dose regime beginning with small dose of
1.5-9 MU, QD with increasing dose at monthly interval
or 3-20 MU, TIW with increasing dose at 3 months in-
terval, this regime usually administrated for
nonresponse.2 With standard-dose Interferon therapy of
3 MU, TIW for 6 months a sustained response rate can
be achieved in only 10-20% of patients.3, 4 High dose
regime may  increase the sustained response rate in some
studies but were associated with more side-effects,
higher cost and discontinuation of treatment.5,7
During the past 5 years the use of Ribavirin as a
synthetic nucleoside analoque in combination with
standard-dose Interferon can increase the sustained
response rate.8, 9
This study reports the results of treatment of chronic
Hepatitis C with high dose Interferon therapy of 6 MU,
TIW for 6 months.
PATIENTS AND METHODS
From February 1996 to February 1998, 15 patients
with chronic Hepatitis C were treated with Interferon
alfa-2b 6 MU, TIW for 6 months. Patients were eligible
if they fulfilled the inclusion criteria: persistently elevated
alanine aminotransferase (ALT) 2 times the upper limit
of the normal range for at least 6 months, positive anti-
HCV and positive HCV-RNA. The exclusion criteria
were decompensated cirrhosis, symptomatic heart
disease, uncontrolled diabetes mellitus and hypertension,
pregnancy and previous treatment with Interferon alfa-
2b. The source of infection was blood transfusion in 3
patient and unknown in 12 patients. Ultrasound-guided
liver biopsy was performed using the Menghini technique
(Hepafix) before and after treatment. Histological
changes were classified as chronic persistent hepatitis,
chronic active hepatitis and cirrhosis. Activity of inflam-
mation classified in 4 grades and fibrosis status in 5
stages. Grade 0: no activity, grade 1: minimal, grade 2:
moderate and grade 3: severe activity.
Stage 0: no fibrosis, stage 1: portal fibrosis, stage 2:
periportal, stage 3: bridging fibrosis and stage 4: cirrhosis.
Clinical and laboratory examinations were done   every
4 weeks during the treatment and during the 6 months
follow-up period, continued every 3-6 months for 1 and
2 years later.
Biochemical and virological responses were assessed
at the end of treatment period week 24 and 48,
continued with examination of ALT every 3-6 months
and HCV-RNA at the end of week 24 and 48.
Patients with elevated ALT or positive HCV-RNA
at the end of treatment were defined as non responders.
Side effects were observed and noted.
RESULTS
Fifteen patients (8 males and 7 females, ages 40 to
60 years) were treated with Interferon alfa-2b, 6 MU,
no TIW for 6 months.
Ten out of 15 patients (66.7%) were HCV-RNA
negative at the end of treatment (at week 24). In 1
patient, the HCV-RNA was negative 3 months later,
while ALT levels were normal at the end of treatment.
In 11 of 15 patients (73.3%) ALT levels were normal at
the end of treatment (week 24).
During the 6 months, follow-up virological relapse was
observed in 5 out of 10 patients (50.0%), and
biochemical relapse in 5 out of 11 patients (45.5%). Thus
at the end of the 6 months follow-up virological sustained
response was found in 5 patients (33.3%), and
biochemical sustained response in 6 patients (40.0%).
After 2 years follow-up, no relapse was found.
If the patient with negative HCV-RNA at 3 months
after the end of treatment is included, the virological
sustained response rate increased from 33.3% to 40.0%
(6 out of 15 patients), and the relapse rate decreased
from 50.0% to 45.5% (5 out of 11 patients), thus
achieving a virological response rate similar to
biochemical response rate (Table 1).
Table 1. Virological and Biochemical Responses at The End of Treatment Week 24 and at 
The End of Follow-up 24 Weeks up to 2 Years 
Virological response Biochemical response  
N 
EOT EOF EOT EOF 
24 weeks 24 weeks 2 years 24 weeks 24 weeks 2 years  
15 10 (66.7%) 6 (40.0%) 6 (40.0%) 11 (73.3%) 6 (40.0%) 6 (40.0%) 
EOT = End of Treatment   
EOF = End of Follow-up 
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Histological changes of 14 patients who underwent 
liver biopsy before treatment showed inflammation  
activity grade 1 in  4 patients and grade 2 in 10 patients.  
Fibrosis stage 1 in 4 patients, stage 2 in 4 patients, stage  
3 in 3 patients and stage 4 (cirrhosis) in 3 patients.  
Histological improvement was found in 4 of 6 patients  
who underwent liver biopsy 1-7 months after treatment,  
8 patients refused a second biopsy. This histological  
improvement was seen mostly in the patients with  
a sustained response. There was no improvement in 2  
patients (Table 2). 
 
 
 
 
 
 
 
 
 
 
Flu-like symptoms were the most common side ef- 
fect, followed by gastrointestinal, dermatological, and 
psychiatic symptoms (Table 3) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DISCUSSION 
Treatment of chronic Hepatitis C with high dose  
Interferon alfa (4.5-10 MU, QD or TIW) as a fixed- 
dose regime has been reported in previous studies. The  
following authors reported an increase of virological  
sustained response rate with high dose Interferon alfa:  
Hakozaki et al (1995) used 6 MU, TIW for 6 months,  
and reported a sustained response rate of 40%. 10 Lino,  
et al (1993) reported a sustained response rate of 48% 
with an induction-dose of 10 MU, TIW for 12 weeks.11 
Yamakawa, et al (1998) reported a 50% sustained  
response rate using an induction-dose of 6 MU, QD for  
2 weeks continued with 6 MU, TIW for 12 weeks.12  
 In contrast, Farell, et al (1997) reported a low  
virological sustained response rate of 14% with 4.5 MU,  
QD for 6 months13, while Lindsay, et al (1996) reported  
a sustained response rate of 17% with 10 MU, TIW for  
6 months.14 
The difference in these results may be caused by the  
difference in methodology and sampling.  
 In this study, we achieved a virological and  
biochemical sustained responses rate of 40.0% if we  
include the patient with late negative HCV-RNA.  
 A similar  case was found in the study by Reichard,  
et al.6 
Histological improvement was observed among 
patients with a sustained response. This finding was also 
found in the study by Davis G. L., et al. in 1998.15 
The histological response in non-responders cannot 
be evaluated due to refusal of a second biopsy.  
 In this study, the incidence of side-effects was higher  
compared to the study by Davis, et al (1998) using an 
Interferon standard dose of 3 MU, TIW for 6 months.16 
However the side-effects did not cause a dose 
reduction or discontinuation of the treatment. 
CONCLUSION 
According to the data reported above, high dose 
Interferon alfa-2b for the treatment of chronic Hepatitis C 
can improve the rate of sustained response. 
The use of high dose Interferon is associated with a 
higher incidence of side-effect, but did not cause dose 
reduction or discontinuation of treatment. 
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Table 2. Histopathological Responses in 6 Patients at 
1-7 Months After Treatment 
Before treatment After treatment  
N 
Grade Stage Grade Stage 
2 II II I I 
1 II I I I 
1 II IV I IV 
1 II II II II 
1 I III I III 
 
Table 3. Side-Effect of Using High Dose Interferon Therapy 
 Flu-like symptoms 
Fever   : 13 patients 
Fatique  : 12 patients 
Malaise  : 10 patients 
Myalgia  : 11 patients 
Headache  : 10 patients 
 Gastrointestinal symptoms 
Anorexia  : 11 patients 
Nausea  :   7 patients 
Weight loss  :   8 patients 
 Dermatological symptoms 
Pruritus  :   3 patients 
Alopecia  :   7 patients 
Dry skin  :   4 patients 
 Psychiatric symptoms 
Depression  :   3 patients 
Emotional lability :   3 patients 
Insomnia  :   4 patients 
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